Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

Staudacher, L.; Cottu, P.; Dièras, Véronique; Vincent‐Salomon, Anne; Guilhaume, M.N.; Escalup, Laurence; Dorval, Thierry; Beuzeboc, Philippe; Mignot, L.; Pierga, Jean‐Yves

doi:10.1093/annonc/mdq461

Cited by 74 publications

(60 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The latter are, in part, BRCA1 mutant breast cancer phenocopies. Multiple clinical trials and retrospective studies of BRCA1 mutant (Silver et al 2010) and sporadic basal-like breast tumors (Sirohi et al 2008;Chew et al 2009;Silver et al 2010;Staudacher et al 2011;Hurley et al 2013) reveal signs of efficacy of the crosslinking agent cisplatin. Cisplatin cross-links cause DNA damage by blocking the procession of transcription or DNA replication (Todd and Lippard 2009).…”

Section: Brca1 Screening and Transcription Damagementioning

confidence: 99%

Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage

et al. 2014

View full text Add to dashboard Cite

BRCA1 is a breast and ovarian tumor suppressor. Given its numerous incompletely understood functions and the possibility that more exist, we performed complementary systematic screens in search of new BRCA1 proteininteracting partners. New BRCA1 functions and/or a better understanding of existing ones were sought. Among the new interacting proteins identified, genetic interactions were detected between BRCA1 and four of the interactors: TONSL, SETX, TCEANC, and TCEA2. Genetic interactions were also detected between BRCA1 and certain interactors of TONSL, including both members of the FACT complex. From these results, a new BRCA1 function in the response to transcription-associated DNA damage was detected. Specifically, new roles for BRCA1 in the restart of transcription after UV damage and in preventing or repairing damage caused by stabilized R loops were identified. These roles are likely carried out together with some of the newly identified interactors. This new function may be important in BRCA1 tumor suppression, since the expression of several interactors, including some of the above-noted transcription proteins, is repeatedly aberrant in both breast and ovarian cancers.

show abstract

Section: Brca1 Screening and Transcription Damagementioning

confidence: 99%

Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Most commonly used platinum agents for TNBC are cisplatin and carboplatin. [4][5][6][7][8] However, only a part of TNBC patients are extremely sensitive to platinum-based chemotherapy, while most of unselected TNBC patients get only substantial toxicities from platinum treatment. 9,10 Hence, the predictive biomarkers are urgently needed to screen out the suitable patients among the unselected groups.…”

Section: Introductionmentioning

confidence: 99%

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy

Jin

Zhang

et al. 2017

Cancer Biology & Therapy

View full text Add to dashboard Cite

Treatment of triple negative breast cancer (TNBC) has been a big challenge since it is defined. To date, platinum-based chemotherapy has played a significant role in the treatment of TNBC patients. However, some patients do not respond to platinum salts or gradually develop chemoresistance, resulting in little effect, or even some adverse effects. Here, we review numerous preclinical and clinical investigations to summarize possible mechanisms and potential predictive biomarkers of platinum in TNBC. The homologous recombination deficiency (HRD) resulting from the loss of BRCA function is the main rationale of platinum efficacy in TNBC. BRCA mutation and methylation have been demonstrated to be important potential biomarkers. Based on genome-wide effects, BRCA-like classifier can identify the functional loss of BRCA and work as the predictor. HRD score that is able to identify the "BRCAness" and predict the sensitivity of platinum is increasingly considered. Taken together, all findings suggest that HR deficiency profile encompassed by BRCA mutation and high HRD score could predict response to platinum, even to other DNA-damage inducing agents. p53 family members and molecular subtypes of TNBC are also important alternative considerations for predicting platinum response based on the preclinical trials. Currently, tumor infiltrating lymphocyte level and thrombocytopenia are emerging as predictive biomarkers.

show abstract

“…They play an important role in the treatment of certain subsets of breast cancer such as TNBC [17]. However, platinum-based drugs are toxic and can be detrimental to nerve and kidney function [18]. Side effects associated with platinating agents include ototoxicity, peripheral neuropathy, myelosuppression, and nephrotoxicity [18].…”

Section: Platinum-based Agentsmentioning

confidence: 99%

“…However, platinum-based drugs are toxic and can be detrimental to nerve and kidney function [18]. Side effects associated with platinating agents include ototoxicity, peripheral neuropathy, myelosuppression, and nephrotoxicity [18]. Another important therapeutic hurdle associated with platinum-based therapy is the formation of platinum resistance in tumours [16].…”

Section: Platinum-based Agentsmentioning

confidence: 99%

Triple Negative Breast Cancer: A review of common therapeutic Targets and Current Treatment options.

Akhtar

Chaudhry

2017

UOJM

View full text Add to dashboard Cite

P a g e 6 0 | U O J M V o l u m e 7 I s s u e 1 | M a y 2 0 1 7Le cancer du sein triple négatif (CSTN) est un sous-type de cancer du sein auquel il manque les récepteurs d'oestrogènes (ER), les récepteurs de progestérone (PR) et l'expression de HER2. Il est caractérisé par un pronostic défavorable et une résistance aux traitements standards du cancer du sein. À l'heure actuelle, la chimiothérapie est encore l'option principale de traitement néoadjuvant pour les patients ayant le CSTN, bien qu'elle ait des niveaux variés d'efficacité sur la survie globale, ainsi que de nombreux effets secondaires sérieux. Les thérapies à base de platine ont été utilisées pour traiter le CSTN en conjonction avec la chimiothérapie, mais elles ne sont pas très efficaces étant donné l'hétérogénéité du CSTN. En raison de cela, d'autres approches novatrices, particulièrement celles qui ciblent les composantes moléculaires impliquées dans la pathogenèse du CSTN, font actuellement l'objet d'enquêtes. Les inhibiteurs de l'angiogenèse, dont les anticorps monoclonaux ou les petites molécules inhibant le VEGF, ont démontré la capacité d'améliorer la survie sans progression de la maladie, mais n'ont pas démontré d'impact sur la survie globale. Les inhibiteurs d'enzymes PARP, lorsque combinés avec la chimiothérapie et le carboplatine pour le traitement du CSTN, ont démontré une réduction significative du risque de progression et de la mortalité. Toutefois, la majorité des inhibiteurs PARP subissent encore des essais et leur efficacité clinique reste à être déterminée. D'autres cibles suggérées pour la thérapie dirigée contre le CSTN incluent les voies de signalisation impliquant le EGFR ou le PI3K. Dans l'ensemble, des problèmes tels la résistance au traitement et les effets secondaires sont des défis importants qui doivent être surmontés afin de permettre des améliorations au niveau du pronostic du patient et de l'impact clinique.

show abstract

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience

Abstract: Metastatic TNBC patients treated with PBCT tended to have a higher response rate, without a significant improvement of PFS or OS, compared with other subtypes. Toxicity was acceptable. Longer observation and further analysis are warranted.

Cited by 74 publications

References 37 publications

Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage

Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage

Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy

Triple Negative Breast Cancer: A review of common therapeutic Targets and Current Treatment options.

Contact Info

Product

Resources

About